Selectivity and Efficacy of CD90-targeted Phase Shift Microbubbles for HIFU-mediated Non-Thermal Ablation of Brain Tumors.

CD90 靶向相移微泡对 HIFU 介导的脑肿瘤非热消融的选择性和功效。

基本信息

项目摘要

ABSTRACT Focused Ultrasound (FUS) is a promising non or minimally invasive treatment modality that can permanently destroy tissue deep within the body using thermal necrosis or mechanical effects and is currently FDA approved to treat essential and Parkinsonian tremor with small thermal ablations. While thermal ablation of tumors with FUS has been attempted, several critical challenges, including long treatment times and small treatment envelopes, have limited these investigations. Combining FUS with acoustically active materials such microbubble (MB) ultrasound contrast agents, amplifies the FUS energy locally. This combination allows for non-thermal ablation (NTA) of tissues by creating ischemic lesions through inertial cavitation of the MBs. The relatively large MB size (1-3 µm) can limit access to the interior of tumors. However, smaller acoustically active materials, such as phase shift microbubbles (PSMB, ~200-300 nm), can more easily penetrate tumors and increase NTA efficiency, potentially overcoming both treatment time and treatment envelope limitations. Microvascular Therapeutics (MVT) has, via the 505(b)(2) pathway, developed a safe and more stable lipid-based MB (MVT- 100) less likely to induce anaphylactoid reactions as compared to Definity®. MVT has subsequently made PSMB from MVT-100 (Patent, US 9,427,410B2) and conjugated MB with a peptide ligand with high affinity for CD90 (CD90-MB). CD90 is a stem cell marker of glioblastoma, and MVT has identified a CD90-binding peptide that recognizes the protein's extracellular domain. Preliminary studies performed by MVT and collaborators at the University of Utah have shown that FUS-NTA performed on a syngeneic rat glioma model allowed for substantially better tumor penetration of non-targeted PSMB compared to MB. In this Phase I SBIR, we will characterize targeted CD90-PSMB and evaluate their selectivity and effectiveness in vivo by performing NTA of brain tumors in a biologically relevant animal model. We hypothesize that CD90-PSMB will improve tumor penetration resulting in improved tumor ablation compared to untargeted PSMB. Our main objective is to evaluate the ability of acoustically activated CD90-PSMB to preferentially conjugate in tumor tissue, and when combined with FUS, safely and efficiently ablate the tumor while sparing surrounding tissues. The overall objectives of this application are to build on the existing collaboration between MVT and University of Utah with the ultimate goal to develop this technology to provide a safe, precise, non-invasive and non-ionizing treatment of brain tumors for the tens of thousands of patients succumbing to brain tumors every year. This project is poised to succeed based on the MVT-100 platform, and to lead to the rapid development of a theranostic agent for treatment of brain tumors in humans in combination with the ExAblate Neuro system by InSightec.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emmanuelle Joelle Meuillet其他文献

Emmanuelle Joelle Meuillet的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emmanuelle Joelle Meuillet', 18)}}的其他基金

Ultrasound-mediated thrombolysis for MVO and PAO treatment.
用于 MVO 和 PAO 治疗的超声介导溶栓。
  • 批准号:
    10447822
  • 财政年份:
    2021
  • 资助金额:
    $ 39.76万
  • 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
  • 批准号:
    8260374
  • 财政年份:
    2010
  • 资助金额:
    $ 39.76万
  • 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
  • 批准号:
    8658015
  • 财政年份:
    2010
  • 资助金额:
    $ 39.76万
  • 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
  • 批准号:
    8088072
  • 财政年份:
    2010
  • 资助金额:
    $ 39.76万
  • 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
  • 批准号:
    7985087
  • 财政年份:
    2010
  • 资助金额:
    $ 39.76万
  • 项目类别:
Inhibition of novel molecular targets of prostaglandin formation for antitumor ac
抑制前列腺素形成的新分子靶点抗肿瘤活性
  • 批准号:
    8447552
  • 财政年份:
    2010
  • 资助金额:
    $ 39.76万
  • 项目类别:
Novel AKT PH domain inhibitors to prevent skin cancer
新型 AKT PH 域抑制剂可预防皮肤癌
  • 批准号:
    7788398
  • 财政年份:
    2009
  • 资助金额:
    $ 39.76万
  • 项目类别:
Novel AKT PH domain inhibitors to prevent skin cancer
新型 AKT PH 域抑制剂可预防皮肤癌
  • 批准号:
    7937893
  • 财政年份:
    2009
  • 资助金额:
    $ 39.76万
  • 项目类别:
Regulation of PTEN Activity in Cancer Cells
癌细胞中 PTEN 活性的调节
  • 批准号:
    6764253
  • 财政年份:
    2002
  • 资助金额:
    $ 39.76万
  • 项目类别:
Regulation of PTEN Activity in Cancer Cells
癌细胞中 PTEN 活性的调节
  • 批准号:
    6916266
  • 财政年份:
    2002
  • 资助金额:
    $ 39.76万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 39.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了